Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.33 |
| ▸ | CLK1 | P49759 | 2/20 | 0.33 |
| ▸ | CLK3 | P49761 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | MAT2A | P31153 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26913996 | 0.80 | MEN1 (0.33) | SIRT2MCL1CLK1CLK3DYRK1A | |
| SCHEMBL26912818 | 0.78 | SIRT2 (0.45) | SIRT2MCL1CLK1CLK3DYRK1A | |
| SCHEMBL26913051 | 0.70 | DCTPP1 (0.37) | MAT2APOLBKMT2A | |
| SCHEMBL26913276 | 0.68 | NOTUM (0.35) | SIRT2NOTUMMAT2ACSNK2A2CSNK2B | |
| SCHEMBL1075595 | 0.67 | POLB (0.48) | MEN1POLBKMT2A | |
| SCHEMBL17700032 | 0.66 | MEN1 (0.32) | NOTUMMEN1KMT2A | |
| SCHEMBL23089259 | 0.62 | PTGDR2 (0.42) | — | |
| SCHEMBL1757919 | 0.62 | AKR1C3 (0.44) | — | |
| SCHEMBL21027586 | 0.61 | PTGDR2 (0.43) | MCL1 | |
| SCHEMBL31025925 | 0.59 | MAPT (0.50) | MCL1CSNK2A2CSNK2BCSNK2A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2023-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391786-A1 | cGAS INHIBITORS | CGAS, STING1, TBK1 | SIRT2 3236/4885MCL1 667/4885NOTUM 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.